Imraldi®

ACTIVE PRINCIPLE:
adalimumab

INDICATION:
Ankylosing spondylitis
Arthritis
Uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis

DATE:
24/08/2017

STATUS:
Authorized

MORE INFORMATION